US20260108454A1: Innate Targeting of Adoptive Cellular Therapies
Summary
USPTO published patent application US20260108454A1 (filed October 30, 2025) for therapeutic methods involving specific repertoires of PRR ligands to provoke innate immune system signaling and facilitate homing of adoptive immune cells to disease sites, particularly solid tumors. The application names inventors Harold David Gunn, David W. Mullins, Mark Bazett, and Shirin Kalyan. This is a publication of a pending application, not a granted patent.
“Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108454A1 for therapeutic methods using specific repertoires of PRR (Pattern Recognition Receptor) ligands to provoke innate immune system signaling, thereby facilitating homing of adoptive immune cells to sites of disease such as solid tumors. The application covers pharmaceutical compositions and methods of treatment employing these modalities. Inventors include Harold David Gunn, David W. Mullins, Mark Bazett, and Shirin Kalyan, with an October 30, 2025 filing date and application number 19374300.
Affected parties include pharmaceutical companies, biotechnology firms, and clinical investigators developing adoptive cell therapies (including CAR-T and similar immunotherapies) for cancer treatment. This publication provides public notice of the intellectual property landscape for PRR-ligand-based homing methods in cellular therapy. Companies engaged in related research should review this application to assess potential freedom-to-operate considerations for their own therapeutic programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Innate Targeting of Adoptive Cellular Therapies
Application US20260108454A1 Kind: A1 Apr 23, 2026
Inventors
Harold David Gunn, David W. Mullins, Mark Bazett, Shirin Kalyan
Abstract
Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.
CPC Classifications
A61K 9/0019 A61K 39/02 A61K 39/39 A61K 40/11 A61K 40/31 A61K 40/32 A61K 40/4202 A61K 40/4255 A61K 40/4273 A61P 35/00 A61P 37/04 C07K 14/7051 A61K 2039/52 A61K 2039/545 A61K 2039/55594 A61K 2239/31 A61K 2239/38 A61K 2239/50 A61K 2239/55 A61K 2239/57 C07K 2319/03
Filing Date
2025-10-30
Application No.
19374300
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.